REFERENCES
1. Assimakopoulos A, Polyzoidis K, Kyritsis AP. Stem Cells in Gliomas. J Stem Cells Res, Rev Rep 2014;1:1009.
2. Kyritsis AP, Levin VA. An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. Cancer Chemother Pharmacol 2011;67:971-83.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2000;352:987-96.
4. Nasseri M, Gahramanov S, Netto JP, Fu R, Muldoon LL, Varallyay C, Hamilton BE, Neuwelt EA. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls rano criteria into question. Neuro Oncol 2014;16:1146-54.
5. Soffietti R, Leoncini B, Ruda R. New developments in the treatment of malignant gliomas. Expert Rev Neurother 2007;7:1313-26.
6. Alexiou GA, Tsiouris S, Voulgaris S, Kyritsis AP, Fotopoulos AD. Glioblastoma multiforme imaging: the role of nuclear medicine. Curr Radiopharm 2012;5:308-13.
7. Assimakopoulos A, Polyzoidis KS, Sioka C. Positron emission tomography imaging in gliomas. Neuroimmunol Neuroinflammation 2014;1:107-14.
8. Alexiou GA, Zikou A, Tsiouris S, Goussia A, Kosta P, Papadopoulos A, Voulgaris S, Tsekeris P, Kyritsis AP, Fotopoulos AD, Argyropoulou MI. Comparison of diffusion tensor, dynamic susceptibility contrast mri and (99m)tc-tetrofosmin brain spect for the detection of recurrent high-grade glioma. Magn Reson Imaging 2014;32:854-9.
9. Alexiou GA, Tsiouris S, Goussia A, Papadopoulos A, Kyritsis AP, Polyzoidis KS, Fotopoulos AD. Evaluation of glioma proliferation by 99mTc-Tetrofosmin. Neuro Oncol 2008;10:104-5.
